QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Large accelerated filer ☐
|
|
Smaller reporting company
|
Non-accelerated filer ☐
|
|
|
|
Emerging growth company
|
•
|
In the VirnetX Inc. v. Apple, Inc. (Case Nos. 6:11-cv-00563-RWS, 6:12-cv-00855-RWS) (“Apple II”) litigation, the United States Court of Appeals for the
Federal Circuit (the “Federal Circuit”) in November 2019, affirmed-in-part, and reversed-in-part the judgment issued by the United States District Court for the Eastern District of Texas (the “district court”) in the case awarding VirnetX
damages of $595.9 million. On October 30, 2020, after a trial in the district court, a jury returned a verdict in favor of VirnetX, awarding VirnetX over $502 million in damages. On January 15, 2021, the district court denied Apple’s
motion for judgment as a matter of law and affirmed the jury findings. This may imply that VirnetX may soon receive over $500 million in cash, however, Apple has appealed to the Federal Circuit with regards to the judgement from the
district court and this appeal is scheduled for oral arguments on September 8, 2022. In addition, the patents in this case are being challenged in the United States Patent and Trademark Office. If those challenges are successful, the
award in the case may be reduced, eliminated and/or delayed for a lengthy period. The continuation of this litigation is distracting to our management, expensive, and these distractions and expenses may continue.
|
•
|
We have undertaken activities to commercialize our products and
patent portfolio in and outside the United States including the successful launch of War Room™ and VirnetX Matrix™. These statements may imply that the worldwide market for our commercialized products is large and will result in
significant future licensing or software revenue for us. However, commercialization of products such as ours is subject to significant obstacles and risks, including but not limited to a perception by some potential partners and customers
that they should await the outcome of the Apple II litigation before entering or considering entering any agreement with us, and that or other factors may prevent significant future revenues for us.
|
Page |
||
2 |
||
2 |
||
2 |
||
3 |
||
4 |
||
5 |
||
6 |
||
7 |
||
18 |
||
21 |
||
21 |
||
22 | ||
22 | ||
22 | ||
37 | ||
SIGNATURES | 38 |
As of
June 30,
2022
|
As of
December 31, 2021
|
|||||||
ASSETS
|
(unaudited)
|
|||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Investments available for sale
|
|
|
||||||
Accounts receivables
|
|
|
||||||
Prepaid expenses and other current assets
|
|
|
||||||
Total current assets
|
|
|
||||||
Prepaid expenses and other assets
|
|
|
||||||
Property and equipment, net
|
|
|
||||||
Deferred tax assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable and accrued liabilities
|
$
|
|
$
|
|
||||
Accrued payroll and related expenses
|
|
|
||||||
Accrued licensing costs
|
|
|
||||||
Other liabilities, current
|
|
|
||||||
Total current liabilities
|
|
|
||||||
Other liabilities |
||||||||
Total liabilities |
||||||||
Commitments and contingencies (Note 4)
|
|
|
||||||
Stockholders’ equity:
|
||||||||
Preferred stock, par value $
|
|
|
||||||
Common stock, par value $
|
|
|
||||||
Additional paid-in capital
|
|
|
||||||
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
Accumulated other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
Total stockholders’ equity
|
|
|
||||||
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
Three Months Ended
|
Six Months
Ended
|
|||||||||||||||
June 30,
2022
|
June 30,
2021
|
June 30,
2022
|
June 30,
2021
|
|||||||||||||
Revenue
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Operating expense:
|
||||||||||||||||
Licensing costs
|
|
|
(
|
)
|
(
|
)
|
||||||||||
Research and development
|
|
|
|
|
||||||||||||
Selling, general and administrative
|
|
|
|
|
||||||||||||
Total operating expense
|
|
|
|
|
||||||||||||
Income (loss) from operations
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Interest and other income, net
|
|
|
|
|
||||||||||||
Income (loss) before taxes
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Income tax (expense) benefit
|
(
|
)
|
(
|
)
|
|
|
||||||||||
Net income (loss)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
Basic income (loss) per share
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
Diluted income (loss) per share
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
Weighted average shares outstanding - basic
|
|
|
|
|
||||||||||||
Weighted average shares outstanding - diluted
|
|
|
|
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
|
June 30,
2022
|
June 30,
2021
|
June 30,
2022
|
June 30,
2021
|
||||||||||||
Net income (loss)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
Other comprehensive income (loss):
|
||||||||||||||||
Change in unrealized gain (loss) on investments, net of tax
|
(
|
)
|
(
|
)
|
(
|
)
|
|
|||||||||
Change in foreign currency translation, net of tax
|
(
|
)
|
|
(
|
)
|
(
|
)
|
|||||||||
Total other comprehensive income (loss)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Comprehensive income (loss)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
Three Months Ended
June 30,
|
Six Months
Ended
June 30,
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
Total shareholders’ equity, beginning balances
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Common stock and additional paid-in capital:
|
||||||||||||||||
Beginning balances
|
|
|
|
|
||||||||||||
Common stock issued for options/RSUs, net
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Stock-based compensation
|
|
|
|
|
||||||||||||
Ending balances
|
|
|
|
|
||||||||||||
Accumulated deficit (retained earnings):
|
||||||||||||||||
Beginning balances
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Net (loss) income
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Ending balances
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Accumulated other comprehensive loss:
|
||||||||||||||||
Beginning balances
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Change in unrealized investment gain/loss, net
|
(
|
)
|
(
|
)
|
(
|
)
|
|
|||||||||
Change in foreign currency translation, net
|
(
|
)
|
|
(
|
)
|
(
|
)
|
|||||||||
Ending balances
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Total shareholders’ equity, ending balances
|
$
|
|
$
|
|
$
|
|
$
|
|
Six Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Cash flows from operating activities:
|
||||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Adjustments to reconcile net (loss) income to cash flows from operating activities:
|
||||||||
Depreciation
|
|
|
||||||
Deferred tax assets
|
(
|
)
|
(
|
)
|
||||
Amortization of warrant issuance costs
|
|
|
||||||
Stock-based compensation
|
|
|
||||||
Changes in assets and liabilities:
|
||||||||
Accounts receivables
|
(
|
)
|
(
|
)
|
||||
Prepaid expenses and other assets
|
(
|
)
|
(
|
)
|
||||
Accounts payable
|
|
(
|
)
|
|||||
Accrued payroll and related expenses
|
|
|
||||||
Accrued licensing costs
|
(
|
)
|
(
|
)
|
||||
Other liabilities
|
( |
) | ( |
) | ||||
Net cash (used in) operating activities
|
(
|
)
|
(
|
)
|
||||
Cash flows from investing activities:
|
||||||||
Purchase of investments
|
(
|
)
|
(
|
)
|
||||
Proceeds from sale or maturity of investments
|
|
|
||||||
Net cash (used in) provided by investing activities
|
(
|
)
|
|
|||||
Cash flows from financing activities: |
||||||||
Payment of payroll taxes on vested restricted stock units |
( |
) | ( |
) | ||||
Net cash used in financing activities |
( |
) | ( |
) | ||||
Net change in cash and cash equivalents
|
(
|
)
|
(
|
)
|
||||
Cash and cash equivalents, beginning of period
|
|
|
||||||
Cash and cash equivalents, end of period
|
$
|
|
$
|
|
||||
Cash paid for income taxes |
$ | $ |
June 30, 2022
|
||||||||||||||||||||||||
Adjusted Cost
|
Unrealized
Gains
|
Unrealized
Losses
|
Fair Value
|
Cash and Cash
Equivalents
|
Investments
Available for
Sale
|
|||||||||||||||||||
Cash
|
$
|
|
$
|
—
|
$
|
—
|
$
|
|
$
|
|
$
|
—
|
||||||||||||
Level 1:
|
||||||||||||||||||||||||
Mutual funds
|
|
|
|
|
|
|
||||||||||||||||||
U.S. agency
securities
|
|
|
(
|
)
|
|
|
|
|||||||||||||||||
U.S. treasury
securities
|
|
|
(
|
)
|
|
|
|
|||||||||||||||||
|
|
(
|
)
|
|
|
|
||||||||||||||||||
Total
|
$
|
|
$
|
4
|
$ | (335 | ) |
$
|
|
$
|
|
$
|
|
December 31, 2021
|
||||||||||||||||||||||||
Adjusted Cost
|
Unrealized
Gains
|
Unrealized
Losses
|
Fair Value
|
Cash and Cash
Equivalents
|
Investments
Available for
Sale
|
|||||||||||||||||||
Cash
|
$
|
|
$
|
—
|
$
|
—
|
$
|
|
$
|
|
$
|
—
|
||||||||||||
Level 1:
|
||||||||||||||||||||||||
Mutual funds
|
|
|
|
|
|
|
||||||||||||||||||
U.S. agency
securities
|
|
|
(
|
)
|
|
|
|
|||||||||||||||||
U.S. treasury
securities
|
|
|
(
|
)
|
|
|
|
|||||||||||||||||
|
|
(
|
)
|
|
|
|
||||||||||||||||||
Total
|
$
|
|
$
|
-
|
$
|
(50
|
)
|
$
|
|
$
|
|
$
|
|
Warrants
Issued
|
Exercise
Price
|
Outstanding and
Exercisable
December 31,
2021
|
Issued
|
Exercised
|
Terminated /
Cancelled
|
Outstanding and
Exercisable
June 30, 2022
|
Expiration Date
|
||||||||||||||||||||
|
$
|
|
|
|
|
|
|
|
Three Months Ended | Six Months Ended | |||||||||||||||
June 30,
|
June 30,
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
Numerator:
|
||||||||||||||||
Net (loss)
income
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
Denominator:
|
||||||||||||||||
Weighted-average
basic shares outstanding
|
|
|
|
|
||||||||||||
Effect of
dilutive securities
|
|
|
|
|
||||||||||||
Weighted-average
diluted shares
|
|
|
|
|
||||||||||||
Basic (loss)
earnings per share
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
Diluted (loss)
earnings per share
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
• |
We may not generate significant sales revenues from our new software products and services.
|
• |
We are involved and will continue to be involved in litigation defending our patent portfolio, which can be time-consuming and costly, and we cannot anticipate the results.
|
• |
We may not be able to capitalize on market opportunities related to our product strategy, our licensing strategy or our patent portfolio.
|
• |
If we are not able to adequately protect our patent rights, our business would be negatively impacted.
|
• |
Because our business is conducted or expected to be conducted in an environment that is subject to rapid change, we may be subject to various developments in regulation, law, and consumer preferences to which we may not be able to
adapt successfully.
|
• |
Our exposure to outside influences beyond our control, including new legislation, court rulings or actions by the USPTO could adversely affect our licensing and enforcement activities and results of operations.
|
• |
New legislation, regulations or court rulings related to enforcing patents could harm our business and operating results.
|
• |
Privacy and data security concerns, and data collection and transfer restrictions and related domestic or foreign regulations may limit the use and adoption of our solutions and adversely affect our business.
|
• |
If we are unable to expand our revenue sources or establish, sustain, grow, or replace relationships with a diversified customer base, our revenues may be limited.
|
• |
We have limited technical resources and are at an early stage in commercialization of our software products.
|
• |
Our international expansion will subject us to additional costs and risks, and our plans may not be successful.
|
• |
We have had to restate our previously issued financial statements and in connection with such process identified a material weakness in our internal control
over financial reporting.
|
• |
We may face litigation over the restatement of our previously issued financial statements.
|
• |
Third parties may challenge the validity of our patents;
|
• |
The pendency of our various litigations may cause potential licensees not to do business with us;
|
• |
Our patents may expire before we can make our business strategy successful;
|
• |
We face, and we expect to continue to face, intense competition from new and established competitors who may have superior products and services or better marketing, financial or other capacities than we do; and
|
• |
It is possible that one or more of our potential customers or licensees develops or otherwise sources products or technologies similar to, competitive with or superior to ours.
|
• |
New legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs and decrease our revenue. For instance, the United States Supreme Court has modified some tests
used by the USPTO in granting patents during the past 20 years which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license. In addition, in 2012 the
United States enacted sweeping changes to the United States patent system under the Leahy-Smith America Invents Act, including changes that transition the United States from a “first-to-invent” system to a “first to file” system and alter
the processes for challenging issued patents;
|
• |
More patent applications are filed each year resulting in longer delays in getting patents issued by the USPTO;
|
• |
Federal courts are becoming more crowded, and as a result, patent enforcement litigation is taking longer; and
|
• |
As patent enforcement becomes more prevalent, it may become more difficult for us to voluntarily license our patents.
|
• |
The need to educate potential customers about our patent rights and our product and service capabilities;
|
• |
The impact of the COVID-19 pandemic on our potential customers and their business operations, including their budgetary constraints and resources devoted to adopting new products.
|
• |
Our customers’ willingness to invest potentially substantial resources and modify their network infrastructures to take advantage of our products;
|
• |
Our customers’ budgetary constraints;
|
• |
The timing of our customers’ budget cycles;
|
• |
Delays caused by customers’ internal review processes; and
|
• |
Long sales cycles that may increase the risk that our financial resources are exhausted before we are able to generate significant revenue.
|
• |
Generate revenues or profit from product sales;
|
• |
Drive adoption of our products;
|
• |
Attract and retain customers for our products;
|
• |
Provide appropriate levels of customer training and support for our products;
|
• |
Implement an effective marketing strategy to promote awareness of our products;
|
• |
Focus our research and development efforts in areas that generate returns on our efforts;
|
• |
Anticipate and adapt to changes in our market; or
|
• |
Protect our products from any system failures or other breaches.
|
• |
Power loss, transmission cable cuts and other telecommunications failures;
|
• |
Damage or interruption caused by fire, earthquake, and other natural disasters;
|
• |
Computer viruses or software defects; and
|
• |
Physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks and other events beyond our control.
|
• |
A staggered Board of Directors: This means that only one or two directors (since we have a five-person Board of Directors) will be up for election at any given annual meeting. This has the effect
of delaying the ability of stockholders to affect a change in control of us because it would take two annual meetings to effectively replace a majority of the Board of Directors.
|
• |
Blank check preferred stock: Our Board of Directors has the authority to establish the rights, preferences, and privileges of our 10,000,000 authorized, but unissued, shares of preferred stock. Therefore, this stock may be issued at
the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock can be used to create a “poison pill” which is
designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of Directors has the ability to do so in the
future, very rapidly and without stockholder approval.
|
• |
Advance notice requirements for director nominations and for new business to be brought up at stockholder meetings: Stockholders wishing to submit director nominations or raise matters to a vote
of the stockholders must provide notice to us within very specific date windows and in very specific form in order to have the matter voted on at a stockholder meeting. This has the effect of giving our Board of Directors and management
more time to react to stockholder proposals generally and could also have the effect of disregarding a stockholder proposal or deferring it to a subsequent meeting to the extent such proposal is not raised properly.
|
• |
No stockholder actions by written consent: No stockholder or group of stockholders may take actions rapidly and without prior notice to our Board of Directors and management or to the minority
stockholders. Along with the advance notice requirements described above, this provision also gives our Board of Directors and management more time to react to proposed stockholder actions.
|
• |
Super majority requirement for stockholder amendments to the bylaws: Stockholder proposals to alter or amend our bylaws or to adopt new bylaws can only be approved by the affirmative vote of at
least 66 2/3% of the outstanding shares of our common stock.
|
• |
No ability of stockholders to call a special meeting of the stockholders: Only the Board of Directors or management can call special meetings of the stockholders. This could mean that
stockholders, even those who represent a significant percentage of our shares of common stock, may need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders.
|
• |
Developments or lack thereof in any then-outstanding litigation;
|
• |
Quarterly variations in our operating results;
|
• |
Large purchases or sales of common stock or derivative transactions related to our stock;
|
• |
Actual or anticipated announcements of new products or services by us or competitors;
|
• |
General conditions in the markets in which we compete; and
|
• |
General social, political, economic, and financial conditions, including the significant volatility in the global financial markets, and impacts from the COVID-19 pandemic.
|
• |
Price and volume fluctuations in the overall stock market from time to time, including fluctuations due to general economic uncertainty or negative market sentiment;
|
• |
Volatility in the market prices and trading volumes of companies in our industry or companies that investors consider comparable;
|
• |
Changes in operating performance and stock market valuations of other companies generally, or those in our industry;
|
• |
Sales of shares of our common stock by us or our stockholders;
|
• |
Failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow us, or our failure to meet these estimates or the expectations of investors;
|
• |
The financial projections we may provide to the public, any changes in those projections or our failure to meet those projections;
|
• |
Announcements by us or our competitors of new products or services;
|
• |
The public’s reaction to our press releases, other public announcements, and filings with the SEC;
|
• |
Rumors and market speculation involving us or other companies in our industry;
|
• |
Actual or anticipated changes in our results of operations;
|
• |
Actual or anticipated developments in our business, our competitors’ businesses, or the competitive landscape generally;
|
• |
Litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;
|
• |
Announced or completed acquisitions of businesses or technologies by us or our competitors;
|
• |
New laws or regulations or new interpretations of existing laws or regulations applicable to our business;
|
• |
Changes in accounting standards, policies, guidelines, interpretations, or principles;
|
• |
Any significant change in our management; and
|
• |
General economic conditions and slow or negative growth of our markets, including any economic downturn from the COVID-19 pandemic.
|
• |
The outcome of actions to enforce our intellectual property rights currently in progress or that we may undertake in the future, and the timing thereof;
|
• |
The impact of the COVID-19 pandemic on our sales cycle and results;
|
• |
The amount and timing of receipt of license fees from potential infringers, licensees, or customers;
|
• |
The rate of adoption of our patented technologies;
|
• |
The number of new license arrangements we may execute, or that may expire, within a particular period and the scope of those licenses, including the number of our patents which are licensed, the extent of prior infringement of our
patent rights, royalty rates, timing of payment obligations, expiration date etc.;
|
• |
The success of a licensee in selling products that use our patented technologies; and
|
• |
The amount and timing of expenses related to our patent filings and enforcement proceedings, including litigation, related to our intellectual property rights.
|
Exhibit
Number
|
Description
|
Certification of the President and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS
|
Inline XBRL Instance Document.
|
101.SCH
|
Inline XBRL Taxonomy Extension Schema Document.
|
101.CAL
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
|
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase Document.
|
101.LAB
|
Inline XBRL Taxonomy Extension Label Linkbase Document.
|
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
|
** |
This exhibit is furnished herewith, but not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to liability under that section. Such certifications will not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except to the extent that we explicitly incorporate them by reference.
|
VIRNETX HOLDING CORPORATION
|
|||
By:
|
/s/ Kendall Larsen
|
||
Name
|
Kendall Larsen
|
||
Chief Executive Officer (Principal Executive Officer)
|
By:
|
/s/ Katherine Allanson
|
||
Name
|
Katherine Allanson
|
||
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
|
|||
Date: August 09, 2022
|
/s/ Kendall Larsen
|
|
Kendall Larsen
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
Date: August 09, 2022
|
/s/ Katherine Allanson
|
|
Katherine Allanson
|
|
Chief Financial Officer
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
|
Date: August 09, 2022
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
/s/ Kendall Larsen
|
|
Kendall Larsen
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
Date: August 09, 2022
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
/s/ Katherine Allanson
|
|
Katherine Allanson
|
|
Chief Financial Officer
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
|
Date: August 09, 2022
|